Table 3.
Selected list of potential actionable targets in urothelial carcinoma identified by metabolomic analysis
| Pathway | Target molecule | Agent |
|---|---|---|
| PPAR |
PPARγ
Dual PPARγ and PPARα |
Thiazolidinediones (Rosiglitazone, Pioglitazone) Muraglitazar, Tesaglitazar |
| Sphingolipid |
Glucosyl ceramide synthase Sphingosine kinase Sphingosine 1‐phosphate receptor Ceramidase |
PPMP, PPPP, etc. SKi, DHS, etc. FTY‐720, LT1002, etc. D‐MAPP, B13, etc. |
| Eicosanoid |
LOX‐5 COX‐2 Dual COX‐2 and COX‐1 Dual LOX‐5 and COX‐2 |
AA861 Celecoxib, Rofecoxib NSAIDs (ibuprofen, aspirin, etc.) Licofelone |
| Heme | HO‐1 |
Metalloporphyrins (ZnPP, SnMP etc.) Imidazole derivatives (Azalanstat, OB‐24) |